Patents Assigned to Celverum Inc.
  • Patent number: 11110138
    Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: September 7, 2021
    Assignee: CELVERUM INC.
    Inventors: David Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
  • Patent number: 9623096
    Abstract: An immunogenic formulation for a patient, the formulation includes virus-modulated hematopoietic cancer cells, where the modulated hematopoietic cancer cells are generated from viable hematopoietic cancer cells obtained from the patient, either isolated or in a mixed hematopoietic population of healthy and cancer cells, and where the viable hematopoietic cancer cells are infected ex vivo with a virus that modulates the expression of a plurality of endogenous immune regulatory molecules to increase the immunogenicity of the hematopoietic cancer cells.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: April 18, 2017
    Assignee: Celverum Inc.
    Inventors: David Conrad, John Cameron Bell, Harry Atkins